BrightSpring Health Services, Inc. Common Stock

Fundamentals5.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • Strong EBITDA
  • Thin net margins
  • High leverage

AI
AI Summary

6.0

BrightSpring has shifted from a leverage‑constrained rollup to a cash‑generating platform with real deleveraging and M&A optionality, but the investment hinges on timely divestiture proceeds and sustained specialty pharmacy/adjusted‑EBITDA growth—watch for confirmed divestiture timing/size, two consecutive quarters of specialty script and EBITDA momentum, and a halt or offset of insider/KKR selling to validate the rerating.

Deleveraging
ExecutionRisk
Catalyst‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • Strong EBITDA
  • Thin net margins
  • High leverage

BTSG delivers solid EBITDA and free cash flow but thin net margins, high leverage, large intangibles and limited cash leave solvency and valuation risks despite scale.

FreeCashFlow
HighLeverage

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Flat last month
  • Buying at ~$38
  • Resistance near $44

Over the last month BTSG was essentially flat (~+0.4%), trading choppily between support near $38.31 and resistance near $43.98, indicating a neutral short-term trend with elevated volatility and reversal risk.

range
volatility
Support Level: $38.31
Resistance Level: $43.98

Sharp swing from $38.31 to $43.98 mid‑March indicates elevated short-term volatility

Sentiment & News

7.0

Key News Insights:

  • Earnings upside
  • Deleveraging plan
  • Institutional inflows

BrightSpring beat expectations, pushed bullish 2026 EBITDA guidance, signaled deleveraging with $2B M&A optionality, and attracted analyst upgrades and institutional buying.

BTSG

Positive operational momentum and clearer capital allocation plans should support the stock's re-rating and near-term upside potential